Mental Health Clinical Trials Market Report 2026

Mental Health Clinical Trials Market Overview

• Mental Health Clinical Trials market size has reached to $3.23 billion in 2025 • Expected to grow to $4.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Mental Health Disorders Fuel Growth In The Market Due To Increasing Stress, Anxiety, And Need For Innovative Therapies • Market Trend: Innovative Digital-First Therapies Accelerate Transformation In Mental Health Research • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mental Health Clinical Trials Market?

Mental health clinical trials are research studies conducted to evaluate the safety, effectiveness, and impact of treatments, interventions, or diagnostic tools for mental health conditions. These trials involve medications, psychotherapy, behavioral therapiesor digital tools to improve mental health care by identifying effective approaches to prevent, manage, or treat mental disorders. The main phases of mental health clinical trials are Phase I, Phase II, Phase III, and Phase IV. A Phase I clinical trial is the first stage of human testing for a new drug, focusing on safety, dosage, and side effects, usually in 20–100 healthy volunteers. These trials utilize various study designs, including interventional, observational, and others and address various disorders including anxiety disorders, depression, bipolar affective disorder, dissociative disorders, schizophrenia, and others. Key sponsors of these trials include pharmaceutical and biopharmaceutical companies, government agencies, and others.

What Is The Mental Health Clinical Trials Market Growth Forecast?

The mental health clinical trials market size is expected to see strong growth in the next few years. It will grow to $4.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of digital mental health interventions, rising investments in personalized psychiatry research, expansion of global mental health trial networks, growing regulatory support for innovative trial designs, increasing use of data-driven outcome assessment. Major trends in the forecast period include increasing adoption of decentralized clinical trial models, rising use of digital therapeutics in trials, growing integration of AI-based patient recruitment tools, expansion of remote patient monitoring in studies, enhanced focus on real-world evidence generation.

What Is The Driver Of The Mental Health Clinical Trials Market?

The rising prevalence of mental health disorders is expected to propel the growth of the mental health clinical trials market going forward. Mental health disorders refer to conditions that significantly affect a person’s emotions, thinking, behaviour, and overall psychological functioning. Mental health disorders are increasing due to rising stress from modern lifestyles, including work pressure, social isolation, and constant digital connectivity. Mental health clinical trials contribute to advancements in care by evaluating the safety and effectiveness of new drugs, therapies, and behavioural interventions for mental health conditions. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, reported that, in 2024, around 43% of adults in the USA were feeling more anxious, an increase from 37% in 2023 and 32% in 2022. Therefore, the rising prevalence of mental health disorders is driving the growth of the mental health clinical trials industry.

Key Players In The Global Mental Health Clinical Trials Market

Major companies operating in the mental health clinical trials market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., Precision for Medicine Inc.

Global Mental Health Clinical Trials Market Trends and Insights

Major companies operating in the mental-health clinical trials market are increasingly focusing on developing innovative solutions such as software-enhanced drug therapies to improve treatment efficacy, personalize patient care, and enhance real-world therapeutic outcomes. Software-enhanced drug therapies are treatments that pair traditional medications with clinically validated therapeutic software, helping improve patient outcomes by personalizing care, boosting adherence, and providing real-time behavioral or symptom-management support. For instance, in October 2024, Click Therapeutics Inc., a US-based digital therapeutics company, launched Click SE, a new offering to pioneer software-enhanced drug therapies that combine prescription software with pharmacotherapy to deliver added clinical benefit and enable novel endpoints in mental-health clinical development. Click SE is a software-centric product family; it is composed of regulated mobile and cloud applications built on Click’s AI-enabled DTx platform. It functions by delivering structured therapeutic programmes, real-time symptom monitoring, and medication-specific digital support designed to synergise with a co-prescribed drug. Unique features include adaptive algorithms that tailor content to patient response, integration pathways for pharmacologic dosing schedules, and built-in metrics for objective trial endpoints; applications span augmentation of antipsychotics for negative symptoms, adjunctive therapy in depression, and support in substance-use disorders.

What Are Latest Mergers And Acquisitions In The Mental Health Clinical Trials Market?

In March 2025, Wysa, a US-based mental health technology company, partnered with April Health Inc. to integrate its AI coach into primary care. This partnership aims to improve mental health access, streamline patient support, and enhance outcomes through continuous, tech-enabled care. April Health Inc. is a US-based digital behavioural health company providing evidence-based mental health care via primary care.

What Defines the Mental Health Clinical Trials Market?

The mental health clinical trials market includes revenues earned by entities through study design, patient recruitment, clinical monitoring, data management, regulatory consulting, site management, and statistical analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mental Health Clinical Trials Market Report 2026?

The mental health clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mental health clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.